On January 16, 2018, Magellan Health announced it was launching a pilot with the PEAR Therapeutics reSET® application for addiction treatment. The U.S. Food and Drug Administration (FDA) approved the reSET application on September 14, 2017. The pilot began in February 2018, and over about six months it will enroll 250 commercial members with substance use disorder (but not opioid use disorder). Each will be offered a 12-week course of reSET® therapy. The goal is to examine the participants’ abstinence and program retention through increased engagement and therapy adherence. The reSET app is a 12-week program available . . .